The regulation of autophagy by dihydroartemisinin involves the modulation of the VEGF pathway and mediation of the PI3K/AKT/mTOR/ULK1 pathway, leading to inhibition of HSCs activation and delayed progression of NAFLD. Here, VEGFA is linked to metabolic dysfunction-associated steatotic liver disease.